🚨Trade Alert 🚨 BNOX

BNOX could see triple-digit gains in its future in the anticipated biotech rebound of 2024!  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ BNOX could see triple-digit gains in its future in the anticipated biotech rebound of 2024! Greetings Investors, Wall Street is embracing a big comeback for the biotech space this year and as things are anticipated to heat up, one company should be high on your radar. Bionomics Limited (NASDAQ: BNOX) may be one of the most exciting comeback stories going undetected on Wall Street.With the Federal Reserve expected to cut interest rates this year, a trend that could continue until 2026, the biotech space could flourish as low-interest rates benefit the industry immensely. And with the surge in innovation including FDA approvals and acquisitions, these tailwinds are bringing biotech out of its 2-year slump. [NASDAQ.com](~/AASl5QA~/RgRnliPSP0SPaHR0cHM6Ly93d3cubmFzZGFxLmNvbS9tYXJrZXQtYWN0aXZpdHkvc3RvY2tzL2Jub3gvYW5hbHlzdC1yZXNlYXJjaD9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2YmFJZnVxcllTanJtSXdJTk9qcE9GOTd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZbHSnrNlQ0ZO41IbdHJpc3RyYW1iYWxkd2luODdAZ21haWwuY29tWAQABeGx)currently shows a “STRONG BUY” rating and a $8 price target! From current levels, this would be a staggering bounce of over 600% if BNOX hits that price! In support of the Company’s transformation into a commercial-stage company, it has expanded the U.S.-based team with new highly experienced management appointments, positioning it to become a leading company in neuropsychiatry. The company has additionally reduced cash burn through efficient capital allocation and has NO outstanding debt, convertible securities, or warrants. Plenty of strategic moves from BNOX management and a promising pipeline indicate that this underfollowed biotech company could be ripe for big gains ahead. [www.bionomics.com.au](~/AASl5QA~/RgRnliPSP0TlaHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPXN6a0VnQmlJTTN5TW96T0JUVmF1eFFGcS15cGdISFIwM2lSQkIzenAxMFM1SUh6dDAza0NtRE92NTEwOGpvaWJFc3doRndWQWlvU1V4c3M3TTlzOGVPTGxjT2VqeVJzdk9OelM4UFEwUkZNJTNEJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZiYUlmdXFyWVNqcm1Jd0lOT2pwT0Y5N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgplsdKes2VDRk7jUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~) Who is BNOX? BNOX is a clinical-stage biotechnology company is developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical needs. Lead Candidate: BNC210… The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). SAD is a significant and persistent fear of social and performance-related situations. One of the most common mental disorders in the United States, an estimated 31 million Americans will suffer from SAD at some point in their lives. Post-traumatic stress disorder (PTSD) is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event. About 5 out of every 100 adults (or 5%) in the U.S. has PTSD in any given year. In 2020, about 13 million Americans had PTSD. ([SOURCE](~/AASl5QA~/RgRnliPSP0TOaHR0cHM6Ly93d3cucHRzZC52YS5nb3YvdW5kZXJzdGFuZC9jb21tb24vY29tbW9uX2FkdWx0cy5hc3A_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmJhSWZ1cXJZU2pybUl3SU5PanBPRjk3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMIzp-OnRleHQ9QWJvdXQlMjA1JTIwb3V0JTIwb2YlMjBldmVyeSxzb21lJTIwcG9pbnQlMjBpbiUyMHRoZWlyJTIwbGlmZS5XA3NwY0IKZbHSnrNlQ0ZO41IbdHJpc3RyYW1iYWxkd2luODdAZ21haWwuY29tWAQABeGx)) Fast Track Designation… The FDA had already granted a Fast Track designation to BNC210, a designation that provides the company with additional market exclusivity and expedited regulatory paths. Fast track designation is designed to aid in the development and expedite the review of drugs that show promise in treating a serious or life-threatening disease and address an unmet medical need. A Partnership with Merck… Beyond BNC210, BNOX has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. BNOX recently revealed positive allosteric modulators (PAMs) of the α7 nicotinic acetylcholine receptor program with Merck & Co., Inc. The ongoing partnership with MSD* on α7 PAMs for the treatment of cognitive disorders such as Alzheimer's disease (AD) and cognitive impairment associated with schizophrenia (CIAS) has generated two clinical candidates that are currently in late Phase 1 clinical development after completing several Phase 1 safety, tolerability, pharmacokinetic and biomarkers studies. The partnership has a potential value of $500m in regulatory and clinical milestones with additional potential royalties from commercialization! Past Gains… BNOX is no stranger to colossal moves, moving over 400% this past fall on positive data results. Could a move like this happen again? Wall Street seems to be reacting optimistically to the company’s recent positive updates on the company’s PTSD (Post Traumatic Stress Disorder) and SAD (Social Anxiety Disorder) Candidate – BNC210. The company’s lead candidate BNC210 looks to be getting closer to the possibility of FDA approval and commercialization! Pivotal Updates… BNOX recently released a review of last year and its plans for 2024. You can read more [HERE.](~/AASl5QA~/RgRnliPSP0SdaHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9uZXdzL2Jpb25vbWljcy1wcm92aWRlcy1yZXZpZXctMjAyMy0yMDI0LTExMDAwMDEzNy5odG1sP19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZiYUlmdXFyWVNqcm1Jd0lOT2pwT0Y5N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgplsdKes2VDRk7jUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~) In 2023 the company continued its evolution into a U.S. focused, late-stage clinical company and finalized the year with strong momentum from a positive readout in a Phase 2b ATTUNE tiral in PTSD and the successful EoP2 meeting with the FDA! All this is also paving the path to a regional study in SAD. “We look forward to continuing to strongly execute, in a timely and fiscally efficient manner, and keep progressing our BNC210 programs in SAD and PTSD while also aiming to establish strategic partnerships in the coming months. Following a transformational 2023 where we delivered on all anticipated milestones, I am confident 2024 will be an exciting year for Bionomics as we keep making strides towards building shareholder value through the development of new treatment options for patients in two psychiatric disorders with significant unmet needs and market potential,” said CEO Dr. Spyros Papapetropoulos. Key Clinical Highlights from 2023… Post-Traumatic Stress Disorder - Positive topline results from the Phase 2b ATTUNE study were announced in September 2023, meeting the primary endpoint on reduction in total symptom severity and highlighting the potential of BNC210 to improve multiple PTSD symptom clusters with notable effects on thought intrusions, mood, trauma-related cognition, and sleep. The BNC210 program is the only non-psychedelic program with a novel mechanism of action to advance in late-stage development in recent years. Social Anxiety Disorder - BNC210 may become the first intermittent “as-needed” non-sedating, non-habit forming, cognitively non-impairing anxiolytic for the treatment of anxiety in patients with SAD. - In March 2023, the Company completed, on time and within budget, the full data analysis of the Phase 2b PREVAIL study demonstrating that BNC210 reduced anxiety during a public speaking challenge and provided support for further evaluation in Phase 3 clinical trials. - A successful EoP2 meeting with the FDA in September 2023 confirmed the Phase 3 enabling nature of the PREVAIL dataset and clarified the plans for the registrational program for BNC210 in SAD, including the number of trials, trial designs, endpoints, sample sizes, size of the safety database and nonclinical requirements for registration. The results of the Phase 2b trials of BNC210 in SAD and PTSD, along with previous results observed in earlier trials in general anxiety disorder (GAD) and panic attacks, underscores BNC210’s potential in multiple, highly prevalent neuropsychiatric indications with significant market opportunity. In Summary… These are exciting times for BNOX and the company’s news should be watched closely. The successful development and commercialization of BNC210 could boost BNOX’s prospects significantly! The stock may still be at a supreme value right now and with strategic moves from management, a promising pipeline, and potential FDA news soon, now is the time to have the company on your radar. BNOX may become one of the biggest biotech movers in 2024 and is currently trading under $1! To reiterate, the stock has a $8 price target! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BNOX. We have been currently compensated up to Fifteen Thousand Dollars Cash ($15,000) via bank wire transfer from a third-party Interactive Offers, LLC for a 1 Day Marketing Program regarding BNOX with a start date of 1/26/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2024 | All rights reserved. [Unsubscribe](~/AASl5QA~/RgRnliPSP0SpaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDhESDJQN0VCQ0RNSlJUNEs2MjIwNCZrPWIyNTkwYjFhMzYyOGZiMmZjOTllZjdhMDZlMWRmYjVjJm09MDFITjFCRDVUWURIRU5FR0VTNVcyNjQ4Q1Imcj0zNUE5NHBLZVcDc3BjQgplsdKes2VDRk7jUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~). [Twitter] [Facebook] [Instagram]